Clinical Trials Browser

Interventional × Neoplasms × talazoparib × Clear all

Lymphoma, Non-Hodgkin, Multiple Myeloma, Neoplasms

NCT01042379 2026-03-13

I-SPY

Phase 2 Recruiting

5,000 enrolled

BreastSarcoma

Pathologic Complete Response, Breast Neoplasms, Hemangiosarcoma, Neoplasms, Triple Negative Breast Neoplasms

NCT04901702 2026-02-09

Study of Onivyde With Talazoparib or Temozolomide in Children With Recurrent Solid Tumors and Ewing Sarcoma

Phase 1/2 Recruiting

90 enrolled

CNSGastrointestinalGenitourinarySarcoma

Neoplasms, Wilms Tumor, Neuroblastoma, Rhabdomyosarcoma, Sarcoma, Sarcoma, Ewing, Osteosarcoma, Hepatoblastoma, Neuroectodermal Tumors, Primitive, Peripheral, Rhabdoid Tumor

NCT02286687 2026-01-02

Talazoparib in Treating Patients With Recurrent, Refractory, Advanced, or Metastatic Cancers and Alterations in the BRCA Genes

Phase 2 Active not recruiting

150 enrolled

Neoplasm Metastasis, Neoplasms, Recurrence

NCT05097599 2025-01-08

StrataPATH

Phase 2 Terminated

11 enrolled

Tumor-Agnostic

Neoplasms

NCT03343054 2024-08-22

A Phase 1 Study Of Talazoparib, PARP Inhibitor, In Japanese Patients With Advanced Solid Tumors

Phase 1 Completed

28 enrolled 43 charts

Breast

Breast Neoplasms, Neoplasms

NCT04801966 2023-05-10

TAILOR

Phase NA Terminated

3 enrolled

Tumor-Agnostic

Neoplasms

NCT02921919 2022-08-24

Open-Label Extension and Safety Study of Talazoparib

Phase 2 Completed

120 enrolled 16 charts

Tumor-Agnostic

Neoplasms

Clinical Trials

TAPUR

I-SPY

Study of Onivyde With Talazoparib or Temozolomide in Children With Recurrent Solid Tumors and Ewing Sarcoma

Talazoparib in Treating Patients With Recurrent, Refractory, Advanced, or Metastatic Cancers and Alterations in the BRCA Genes

StrataPATH

A Phase 1 Study Of Talazoparib, PARP Inhibitor, In Japanese Patients With Advanced Solid Tumors

TAILOR

Open-Label Extension and Safety Study of Talazoparib